Although randomized controlled trials have consistently shown that selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) significantly reduce the incidence of estrogen receptor–positive (ER+) breast cancer, real-world data reveal that adverse effects often undermine their sustained use [9,10,50]. The gene discussed is CYP19A1; the disease is breast carcinoma.